Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director · PRESIDENT AND CEO | January 02, 2026 | January 06, 2026 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Director | June 15, 2020 | June 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 50,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 675,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 675,000 · Balance 675,000 F1: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 112,500 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 112,500 · Balance 112,500 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.
Turning Point Therapeutics, Inc.
Report date June 15, 2020 · Filed June 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.39 · Expires 2030-06-14 | Direct | 8,500 |
Reported balance
After 2020-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-15 · Grant · Acquired 8,500 · Balance 8,500 F1: The shares vest on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the one-year anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 70,572 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2024-05-29 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.58 · Expires 2025-01-07 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-08 · Disposition to issuer · Disposed 25,200 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-08 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").
F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:28 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001193125-26-276138 · ownership.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-26-000002 · form4-01062026_090105.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 675,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001608936-26-000002 · form4-01062026_090105.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 33,374 | $9.06 | $302,368.44 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,711 F2 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · derivative · entry 5 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 28,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,334 Underlying: Common Stock · 28,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F4 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F4 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 83,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:35 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 37,461 | $12.32 | $461,519.52 |
DisclosureSEC source: 0001608936-25-000010 · form4-10082025_091029.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 531,419 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 37,461 shares sold in the price range of $12.07 to $12.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 53,001 | $12.05 | $638,805.15 |
DisclosureSEC source: 0001608936-25-000008 · form4-10022025_111028.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 568,880 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025. F4 · price: Represents the weighted average share price of an aggregate total of 53,001 shares sold in the price range of $12.00 to $12.13 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 34,538 | $12.01 | $414,749.57 |
DisclosureSEC source: 0001608936-25-000008 · form4-10022025_111028.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 621,881 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 34,538 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:30 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 125,000 | $10.80 | $1,349,937.50 |
DisclosureSEC source: 0001608936-25-000006 · form4-09242025_080916.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 656,419 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 125,000 shares sold in the price range of $10.57 to $10.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. F4 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000950170-25-088497 · ownership.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:41 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000600 · form4-01032025_100156.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:41 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001415889-25-000600 · form4-01032025_100156.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 24,660 | $8.28 | $204,214.39 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778,648 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 24,660 shares sold in the price range of $8.27 to $8.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 28,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · derivative · entry 5 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,667 Underlying: Common Stock · 28,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 67,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 803,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:17 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right To Buy) · Derivative | 22,500 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0000950170-24-064221 · ownership.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-05-20 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:20 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 40,000 | $16.21 | $648,380.00 |
DisclosureSEC source: 0001415889-24-007345 · form4-03082024_090337.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,544 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $16.00 to $16.43 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 01:01 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 26,042 | $12.30 | $320,186.39 |
DisclosureSEC source: 0001415889-24-003114 · form4-02092024_010219.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,544 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F3 · price: Represents the weighted average share price of an aggregate total of 26,042 shares sold in the price range of $12.11 to $12.40 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 01:01 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 13,958 | $12.12 | $169,159.79 |
DisclosureSEC source: 0001415889-24-003114 · form4-02092024_010219.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794,586 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 13,958 shares sold in the price range of $12.00 to $12.31 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000361 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:17 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 510,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-24-000361 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,000 Underlying: Common Stock · 510,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 22,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 14,539 | $8.58 | $124,812.95 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,544 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 14,539 shares sold in the price range of $8.57 to $8.77 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 38,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes 3,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 01:28 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 5,156 | $8.01 | $41,287.19 |
DisclosureSEC source: 0001209191-23-042054 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,652 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F3 · price: Represents the weighted average share price of an aggregate total of 5,156 shares sold in the price range of $8.00 to $8.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:28 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 10,508 | $8.01 | $84,212.16 |
DisclosureSEC source: 0001209191-23-042054 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 785,808 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 10,508 shares sold in the price range of $8.00 to $8.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:35 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 4,336 | $8.01 | $34,710.55 |
DisclosureSEC source: 0001209191-23-041805 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 796,316 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 4,336 shares sold in the price range of $8.00 to $8.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 20,000 | $8.03 | $160,562.00 |
DisclosureSEC source: 0001209191-23-040090 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,652 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $8.00 to $8.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 4,000 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| May 23, 2023 Filed May 25, 2023 23:32 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001610717-23-000068 · form4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:43 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.41 | $0.00 |
DisclosureSEC source: 0001140361-23-020315 · form4.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 5,000 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:43 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 5,000 | $20.05 | $100,269.50 |
DisclosureSEC source: 0001140361-23-020315 · form4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.00 to $20.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:43 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 5,000 | $9.41 | $47,050.00 |
DisclosureSEC source: 0001140361-23-020315 · form4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:09 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006191 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:09 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006191 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061754 · doc4.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F4 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F4 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 5,764 | $3.25 | $18,733.00 |
DisclosureSEC source: 0001209191-22-061754 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,025 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061754 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 3,471 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2022 Filed Feb 17, 2023 21:22 UTC Amendment | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 6,137 | $3.07 | $18,859.00 |
DisclosureSEC source: 0001209191-23-010607 · doc4a.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,652 F1 · kind: This amendment is filed to correct the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. F1 · shares: This amendment is filed to correct the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. F1 · price: This amendment is filed to correct the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 300,000 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042841 · doc4.xml · derivative · entry 6 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F6 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 280,000 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042841 · doc4.xml · derivative · entry 5 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F6 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 437,500 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042841 · doc4.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 437,500 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F5 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 300,000 | Not disclosed Strike: $9.48 | Not disclosed |
DisclosureSEC source: 0001209191-22-042841 · doc4.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2032-01-31 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F4 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 280,000 | Not disclosed Strike: $29.83 | Not disclosed |
DisclosureSEC source: 0001209191-22-042841 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280,000 shares Expires 2031-01-31 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F3 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 437,500 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-042841 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 437,500 shares Expires 2030-04-22 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.